Butterfly Network, Inc. (BFLY)
USD 3.12
(-11.36%)
USD 3.12
(-11.36%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -124.84 Million USD | 36.35% |
| 2022 | -162.74 Million USD | 3.69% |
| 2021 | -29.54 Million USD | -18.0% |
| 2020 | -160.24 Million USD | -63.3% |
| 2019 | -98.93 Million USD | -87.76% |
| 2018 | -52.69 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -17.24 Million USD | -9.27% |
| 2024 Q1 | -18.68 Million USD | 54.93% |
| 2024 Q2 | -13.99 Million USD | 32.46% |
| 2023 Q1 | -32.72 Million USD | 28.4% |
| 2023 FY | - USD | 36.35% |
| 2023 Q3 | -26.85 Million USD | 9.57% |
| 2023 Q2 | -29.69 Million USD | 9.29% |
| 2023 Q4 | -44.17 Million USD | -64.52% |
| 2022 Q1 | -48.78 Million USD | -6.68% |
| 2022 Q2 | -47.23 Million USD | 3.18% |
| 2022 FY | - USD | 3.69% |
| 2022 Q4 | -45.7 Million USD | -4.48% |
| 2022 Q3 | -43.75 Million USD | 7.37% |
| 2021 Q2 | -35.88 Million USD | 33.72% |
| 2021 FY | - USD | -18.0% |
| 2021 Q4 | -45.72 Million USD | 18.37% |
| 2021 Q3 | -56.01 Million USD | -56.1% |
| 2021 Q1 | -54.14 Million USD | -148.35% |
| 2020 Q1 | -24.05 Million USD | 40.27% |
| 2020 Q4 | -21.8 Million USD | 76.2% |
| 2020 Q3 | -91.58 Million USD | -301.51% |
| 2020 Q2 | -22.81 Million USD | 5.17% |
| 2020 FY | - USD | -63.3% |
| 2019 FY | - USD | -87.76% |
| 2019 Q4 | -40.26 Million USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott Laboratories | 10.46 Billion USD | 101.193% |
| Allurion Technologies Inc. | -69.03 Million USD | -80.852% |
| Artivion, Inc. | 38.14 Million USD | 427.314% |
| Avanos Medical, Inc. | 53.2 Million USD | 334.669% |
| Butterfly Network, Inc. | -124.84 Million USD | -0.0% |
| Bio-Rad Laboratories, Inc. | -608.26 Million USD | 79.475% |
| Boston Scientific Corporation | 3.45 Billion USD | 103.616% |
| Perspective Therapeutics, Inc. | -14.83 Million USD | -741.38% |
| CONMED Corporation | 182.18 Million USD | 168.526% |
| Edwards Lifesciences Corporation | 1.76 Billion USD | 107.063% |
| Paragon 28, Inc. | -36.61 Million USD | -240.973% |
| Glaukos Corporation | -82.11 Million USD | -52.034% |
| Globus Medical, Inc. | 418.23 Million USD | 129.85% |
| Inspire Medical Systems, Inc. | -17.06 Million USD | -631.794% |
| Integer Holdings Corporation | 282.05 Million USD | 144.262% |
| Medtronic plc | 9.05 Billion USD | 101.379% |
| Nevro Corp. | -78.31 Million USD | -59.423% |
| Owlet, Inc. | -27.48 Million USD | -354.16% |
| Penumbra, Inc. | 111.99 Million USD | 211.472% |
| Vicarious Surgical Inc. | -69.19 Million USD | -80.431% |
| Smith & Nephew plc | 979 Million USD | 112.752% |
| Sonendo, Inc. | -54.76 Million USD | -127.951% |
| STERIS plc | 1.41 Billion USD | 108.839% |
| Stryker Corporation | 5.16 Billion USD | 102.419% |
| Vapotherm, Inc. | -34.35 Million USD | -263.373% |
| Zimmer Biomet Holdings, Inc. | 2.44 Billion USD | 105.098% |